Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
How AI fixed the James Webb Space Telescope's blurry vision - 2Misremembering might actually be a sign your memory is working optimally
- 3Andrew McCarthy's awe-inspiring image of a skydiver in front of the sun
- 4What to watch for as NASA’s historic Artemis II crew prepares to lift off toward the moon
- 5Transcript: Scott Gottlieb on "Face the Nation with Margaret Brennan," Dec. 7, 2025
- Scientists train to dive beneath polar ice as climate change warms the Arctic and Antarctica
- What's an atmospheric river? AP explains the weather phenomenon
- Hostile to Maturing Skincare Items to Rejuvenate Your Skin
- Child influencers helped power a booming industry. It's time for a reckoning.
- 10 Setting up camp Shelters That Offer Both Excellence and Isolation
- Tehran synagogue damaged by missile strike according to Iranian media
- EU foreign ministers commemorate Russian massacre in Bucha
- Red Sea arena: Yemen’s Houthis open fourth front in Iran war, with global implications
- Hitting the brakes: Hubble Space Telescope watches doomed comet reverse its spin
